Interviews

Paul Garofolo

2024-04-27

Ultimately, our aim is to develop targeted therapies against major pathogenic threats, as we believe precision in treating diseases caused or exacerbated by bacteria is crucial for the future of medicine.

Phil Murphy

Governor

New Jersey

2024-04-27

The creation of Strategic Innovation Centers across the state, in conjunction with programs such as NJ Ignite, which provides rent support grants to entrepreneurs, and NJ Accelerate, which expands accelerator spaces, ensures that affordable lab and R&D space is available to inventive companies.

Mitchell Toomey

VP Sustainability & Responsible Care,

American Chemistry Council

2024-04-26

We are committed to tracking and managing our environmental impact, going beyond regulatory requirements with our Responsible Care programs. Our industry not only focuses on managing emissions but also plays a crucial role in reducing emissions across various sectors through our products and innovations.

Katherine Stueland

Chief Executive Officer

GeneDx

2024-04-26

GeneDx aims to make genomic information accessible for broad populations to enable proactive health management.

Timothy T. Goodnow and Brian Hansen

President & CEO and President

Senseonics and Ascensia Diabetes Care

2024-04-26

The partnership between Senseonics and Ascensia Diabetes Care’s CGM team, under the leadership of Brian Hansen, is pivotal for leveraging global commercialization opportunities.

Rob Schumm

President of BGM

Ascensia Diabetes Care

2024-04-26

This advancement positions Ascensia as a leader in blood glucose monitoring, offering devices that are not only highly accurate but also user-friendly.

Tarek Rabah

CEO

Otsuka NA

2024-04-26

Otsuka is actively addressing the need for more diverse and inclusive clinical trials by recruiting investigators from various backgrounds and including trial sites in underrepresented communities.

Tamer Mohamed

CEO

Aspect Biosystems

2024-04-26

Aspect Biosystems is currently experiencing a period of strategic growth, focusing on expanding our therapeutic pipeline in the metabolic and endocrine space.

Terrie Curran

President & CEO

Phathom Pharma

2024-04-26

Our ambitious clinical program aims to expand treatment options for various GERD-related conditions, demonstrating our commitment to addressing unmet needs in gastrointestinal care.

Quentin Blackford

President & CEO

iRhythm Technologies

2024-04-25

In the next five years, I envision iRhythm playing a pivotal role in detecting, predicting, and preventing disease on a global scale. While our initial focus was on cardiac health, our future includes expanding into adjacent markets like sleep disorders, hypertension, and heart failure.

Pagina 57 din 154